Loading…
Immunic, Inc. is projected to rise to $21.78 by 2027, a +56% move from its current price of $14.00. IMUX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.40 | $14.02 | $14.66 | +0.14% |
| May 30 | $13.17 | $14.04 | $14.96 | +0.28% |
| May 31 | $13.01 | $14.06 | $15.20 | +0.41% |
| Jun 1 | $12.87 | $14.08 | $15.40 | +0.55% |
| Jun 2 | $12.75 | $14.10 | $15.59 | +0.69% |
| Jun 3 | $12.64 | $14.12 | $15.76 | +0.83% |
| Jun 4 | $12.55 | $14.14 | $15.92 | +0.97% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.55 | $14.14 | $15.92 | +0.97% |
| Week 2 | $12.06 | $14.27 | $16.89 | +1.95% |
| Week 3 | $11.73 | $14.41 | $17.71 | +2.94% |
| Week 4 | $11.47 | $14.55 | $18.46 | +3.94% |
| Week 5 | $11.26 | $14.69 | $19.17 | +4.94% |
| Week 6 | $11.09 | $14.83 | $19.85 | +5.96% |
| Week 7 | $10.94 | $14.98 | $20.52 | +6.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunic, Inc. is a biotechnology company that develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Immunic, Inc. (IMUX) trades at $14.00 per share, with a market cap of $190.7M, and a rank of 3827.
The near-term forecast for 2026 shows an average price of $14.00, a neutral sentiment, and an ROI of 0%. The 2026 forecast also provides a min of $5.83 and a max of $23.66.
From 2027 onward, the forecast envisions a bullish trajectory, with the average price rising to $21.78 in 2027, $24.91 in 2028, $26.42 in 2029, and $28.42 in 2030, accompanied by rising ROIs (55.6% in 2027, 77.9% in 2028, 88.7% in 2029, and 103% in 2030). The bullish path continues through 2031 ($37.46, 167.6%), 2032 ($46.01, 228.6%), 2033 ($57.14, 308.1%), 2034 ($70.29, 402%), 2035 ($68.25, 387.5%), 2040 ($136.31, 873.7%), and 2050 ($239.27, 1609.1%).
A major floor 57.9% below — a decisive break under it would weaken the trend.
The nearest floor, 37.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 24.8% above — clearing it would confirm fresh momentum.
Key IMUX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMUX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.77 | Buy | $13.02 | Buy |
| MA 10 | $12.48 | Buy | $12.53 | Buy |
| MA 20 | $11.72 | Buy | $11.98 | Buy |
| MA 50 | $11.35 | Buy | $11.21 | Buy |
| MA 100 | $9.85 | Buy | $10.32 | Buy |
| MA 200 | $8.83 | Buy | $9.69 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.41 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 179.21 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.20 | Buy |
| ROC (12) | 20.38 | Buy |
| Bollinger %B (20,2) | 1.01 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.51 | Buy |
| Awesome (5,34) | 1.59 | Buy |
| Ultimate (7,14,28) | 76.35 | Sell |
| Momentum (10) | 2.10 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 13.45 | Buy |
| ADX (14) | 16.60 | Neutral |
| ATR (14) | 0.50 | Info |
The 30-day technical picture is bullish. The RSI(14) is 70, indicating strong positive momentum. The stock trades above the SMA50 at $11.35 and above the SMA200 at $8.83, suggesting an uptrend.
Support is at $8.80 and resistance at $14.00, with the 30-day price range spanning $10.41 to $18.83, indicating recent volatility within a rising channel.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.83 | $14.00 | $23.66 | 0% | Neutral | |
| $16.19 | $21.78 | $31.56 | +56% | Bullish | |
| $17.65 | $24.91 | $38.09 | +78% | Bullish | |
| $17.96 | $26.42 | $42.12 | +89% | Bullish | |
| $18.62 | $28.42 | $46.92 | +103% | Bullish | |
| $23.71 | $37.46 | $63.75 | +168% | Bullish | |
| $28.18 | $46.01 | $80.43 | +229% | Bullish | |
| $33.93 | $57.14 | $102.35 | +308% | Bullish | |
| $40.50 | $70.29 | $128.73 | +402% | Bullish | |
| $38.20 | $68.25 | $127.60 | +388% | Bullish | |
| $66.41 | $136.31 | $277.41 | +874% | Bullish | |
| $107.67 | $239.27 | $549.35 | +16.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.83 | $14.00 | $16.63 | +0.00% |
| June 2026 | $12.63 | $15.05 | $18.50 | +7.48% |
| July 2026 | $13.14 | $15.88 | $19.95 | +5.50% |
| August 2026 | $12.82 | $15.66 | $20.00 | -1.38% |
| September 2026 | $12.93 | $15.93 | $20.62 | +1.77% |
| October 2026 | $13.81 | $17.17 | $22.49 | +7.76% |
| November 2026 | $14.13 | $17.70 | $23.43 | +3.08% |
| December 2026 | $14.03 | $17.70 | $23.66 | -0.01% |
Click any year to see its month-by-month IMUX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IMUX to range from $5.83 to $23.66 through 2026. The $14.00 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IMUX price prediction for 2027 points to an average of $21.78 (low $16.19, high $31.56) — a potential gain of +56% on today's $14.00. Buyers look set to stay in control over this stretch.
In 2028, IMUX is projected to trade between $17.65 and $38.09, averaging $24.91 — a potential gain of +78% from today's $14.00. That is up +14% on the projected 2027 average. Momentum favours further upside here.
Immunic, Inc.'s 2029 outlook centres on $26.42, within a $17.96 to $42.12 range. That is up +6% on the projected 2028 average. That marks a +89% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IMUX could reach as high as $46.92, with a base case around $28.42 and support toward $18.62 — roughly +103% from $14.00. Momentum favours further upside here.
Expect IMUX to range from $23.71 to $63.75 through 2031. The $37.46 average target implies a +168% move from current prices. That is up +32% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The IMUX price prediction for 2032 points to an average of $46.01 (low $28.18, high $80.43) — a potential gain of +229% on today's $14.00. Momentum favours further upside here.
In 2033, IMUX is projected to trade between $33.93 and $102.35, averaging $57.14 — a potential gain of +308% from today's $14.00. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Immunic, Inc.'s 2034 outlook centres on $70.29, within a $40.50 to $128.73 range. That is up +23% on the projected 2033 average. That marks a +402% change versus current levels. Momentum favours further upside here.
By 2035, IMUX could reach as high as $127.60, with a base case around $68.25 and support toward $38.20 — roughly +388% from $14.00. Buyers look set to stay in control over this stretch.
Expect IMUX to range from $66.41 to $277.41 through 2040. The $136.31 average target implies a +874% move from current prices. That is up +100% on the projected 2035 average. Momentum favours further upside here.
The IMUX price prediction for 2050 points to an average of $239.27 (low $107.67, high $549.35) — a potential gain of +16.1x on today's $14.00. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMUX today (≈ 71.428571 IMUX) could be worth
$17,090.95
+$16,090.95 (+1609%) by 2050 · US Dollar
Based on the average projected IMUX price of $239.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMUXwould be worth at today's price.
$1,000 invested in IMUX on May 27, 2025 (≈ 112.359555 IMUX) would be worth
$1,573.03
+$573.03 (+57.3%) today · 1.57× · US Dollar
Based on a IMUX entry price of $8.9 vs. today's $14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.55 | $1,212.12 | +21.2% |
| 1 month ago | $9.98 | $1,402.81 | +40.3% |
| 3 months ago | $9.48 | $1,476.79 | +47.7% |
| 6 months ago | $7.12 | $1,966.29 | +96.6% |
| 1 year ago | $8.9 | $1,573.03 | +57.3% |
| All time (5.0y) ago | $135.8 | $103.09 | -89.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMUX forecast.
Our base-case forecast reaches $28.00 around 2030.
Implied market cap at $28.00: $381.4M
The multi-year forecast shows a bullish trajectory with rising average prices and high upside potential through 2050. The projected average price climbs from $14.00 in 2026 to $239.27 in 2050, with notable milestones such as $28.42 by 2030, $136.31 by 2040, and $239.27 by 2050. ROIs grow from 0% in 2026 to 103% in 2030 and reach 1609.1% by 2050, with sentiment staying BULLISH across the longer horizon.
These figures are estimates and not guarantees. They reflect the modeled outlook given the provided inputs and carry inherent uncertainty and risk, including high volatility, as indicated by the 90% annualized volatility. Investors should approach with caution and consider the full range of possible outcomes.
Tap a question to reveal the answer.
The forecast average price for 2030 is $28.42, with a min of $18.62 and a max of $46.92. The ROI is 103% and the sentiment is BULLISH.
The forecast projects a bullish path from 2027 onward, with rising average prices and higher ROIs (e.g., 55.6% in 2027, 1609.1% by 2050). The 2026 outlook is Neutral with an average of $14.00 and ROI of 0%.
Yes. The forecast max by 2033 is $102.35 and by 2034 is $128.73, indicating the asset could exceed $100 in the 2030s, with a bullish long-run trend.
Current price is $14.00 per share and market cap is $190.7M.
The 30-day range is from a low of $10.41 to a high of $18.83.
Immunic, Inc. Community Discussion
0Share your Immunic, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.